| Acquired by | Amgen |
| Price | $315M |
| Date | 4/12 |
| Terms | Cash |
| Website | kaipharmaceutical... |
| Category | BioTech |
| Phone | 650-244-1100 |
| info@kaipharma.com | |
| Employees |
| TOTAL | $35M |
| FUNDING TOTAL | $35M |
| Series B, 5/06 Investor Growth Capital Aberdare Ventures Skyline Ventures InterWest Partners InterSouth Partners Delphi Ventures MDS Capital | $35M |
KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI’s lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI’s second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.
